D&D Pharmatech Inc. Logo

D&D Pharmatech Inc.

Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.

347850 | KO

Overview

Corporate Details

ISIN(s):
KR7347850000
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 금토로80번길 27 (금토동, 텔레칩스) 4층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

D&D Pharmatech Inc. is a clinical-stage global biotechnology company focused on developing novel peptide-based therapies for metabolic and chronic diseases with high unmet medical needs. The company's core research centers on its portfolio of GLP-1 (Glucagon-like peptide-1) class drugs, targeting conditions such as obesity and MASH (Metabolic dysfunction-associated steatohepatitis). A key competency is its advanced oral peptide technology, which enables the creation of oral treatments in addition to injectable therapies. D&D Pharmatech operates a dual-center model, with a research team in Korea dedicated to peptide discovery and a clinical development team in the United States managing global trials and regulatory processes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-16 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.4 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 180.8 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.1 KB
2025-06-19 00:00
Regulatory News Service
기타경영사항(자율공시) (국책과제 선정(국가신약개발사업(R&D) (대사이상 관련 지방간염(MASH) 치료제 DD01 개…
Korean 7.9 KB
2025-06-17 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-06-16 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline …
Korean 12.8 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-11 00:00
Capital/Financing Update
주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 31.4 KB

Automate Your Workflow. Get a real-time feed of all D&D Pharmatech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for D&D Pharmatech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for D&D Pharmatech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.